Rallybio Corporation

NASDAQ:RLYB

Biotechnology

Healthcare
$15.26 +0.03%

+$0.01 today

Market cap
$82.16M
Beta
-0.88
P/E (TTM)
-11.6
EPS (TTM)
-$1.37
52W Low $2.40High $17.57

Volume 0.03M

Average 0.25M

RLYB Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Rallybio CorporationNASDAQ: RLYB

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $3K fell 89.3% year over year, behind the -46.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Cost of revenue amounted to 10.7% of revenue in FY2025, down 9.9 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -89.3% toward the trailing-twelve-month pace of -46.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3K+0.0% QoQ
Last fiscal yearDec 2025
$92K-29.8% YoY
LTMMar 2026
$67K-46.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.3%——
1 year-29.8%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
92K USD
Year-over-year change
-29.8%
4-year CAGR
-4.2%

Cost of Revenue vs competitors

How RLYB compares with its peers on the latest reported figures

  • RLYB's LTM Mar 2026 cost of revenue of $67K is the 3rd highest of the 4 companies compared; the peer median is $362K.
  • Its year-over-year change of -46.0% is the lowest of 3, against a peer median of +180.1%.
  • Cost of revenue amounts to 7.8% of revenue for RLYB, versus a peer median of 0.3%.
RLYB Competitors Peer median
Cost of Revenue for RLYB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BOLDBoundless Bio, Inc.LTM Mar 2026$1.22M +359.6%——
QTTBQ32 Bio Inc.LTM Mar 2026$362K +0.6%-46.8%0.7%
RLYBRallybio CorporationLTM Mar 2026$67K -46.0%-18.0%7.8%
IBIOiBio, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding RLYB) $362K+180.1%-46.8%0.3%

Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000636K858K
Cost of Revenue109K167K150K131K92K
Gross Profit(109K)(167K)(150K)636K766K
Gross Margin———100.0%89.3%
Research & Development26.91M40.69M53.54M41.51M19.6M
Selling, General & Admin18.74M27.2M25.39M19.63M14.33M
Operating Expenses45.65M67.88M78.93M61.13M28.83M
Depreciation & Amortization109K167K150K131K92K
EBITDA(45.39M)(67.72M)(78.78M)(60.37M)(27.97M)
EBITDA Margin———-9491.4%-3260.1%
Operating Income(45.65M)(67.88M)(78.93M)(60.5M)(28.06M)
Operating Margin———-9511.9%-3270.9%
Interest Income54K1.96M6.15M4.22M2.19M
Interest Expense10K0000
Other Income / Expenses(1.37M)1.23M4.37M2.72M19.09M
Income Before Tax(47.01M)(67.73M)(74.56M)(57.78M)(8.98M)
Pre-Tax Margin———-9084.1%-1046.4%
Income Tax Expense0(1.08M)000
Net Income(47.01M)(66.65M)(74.56M)(57.78M)(8.98M)
Net Margin———-9084.1%-1046.4%
EPS (Basic)(11.68)(16.72)(14.72)(10.64)(1.59)
EPS (Diluted)(11.68)(16.72)(14.72)(10.64)(1.59)
Weighted Avg Shares4.02M3.98M5.06M5.44M5.63M
Weighted Avg Shares (Diluted)4.02M3.98M5.06M5.44M5.63M

Rallybio Corporation

NASDAQ:RLYB

Intrinsic Alpha fair value

Locked

Current Price

$15.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.